Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Vinpocetine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Noopept and Vinpocetine have evidence — compare verdict strength side-by-side.
10-30mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, Sublingual for faster onset
Noopept powder (sublingual) or capsules
10-30mg daily in divided doses
With food (improves absorption), Divided into 2-3 doses, Morning and early afternoon
Vinpocetine capsules or tablets
1-2 weeks
Acute to 1 week
Ongoing
With higher doses
2-4 weeks
1-2 weeks
2-4 weeks
First few days
Novel Technologies for Dipeptide Drugs Design and their Implantation
Current pharmaceutical design (2018) · Systematic review
The latter usually corresponds to a beta-turn of some regulatory peptide.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Journal of biomedical science (2014) · Observational
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
Neuroscience and behavioral physiology (2009) · Observational
Clinical trial examining Noopept efficacy
Efficacy and safety of herbal medicine on dementia and cognitive function: An umbrella review of systematic reviews and meta-analysis
Phytotherapy research : PTR (2023) · Meta analysis
Of these, 65% were rated critically low using AMSTAR2.
Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications
Oxidative medicine and cellular longevity (2021) · Systematic review
Among them, scutellarin, pinocembrin, puerarin, hydroxysafflor yellow A, salvianolic acids, rosmarinic acid, borneol, bilobalide, ginkgolides, ginsenoside Rd, and vinpocetine show great potential in clinical ischemic stroke treatment.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Based on RCT with n=60 showing MMSE improvements after 2 months. Most studies lack placebo controls and have small sample sizes. Effectiveness may be overestimated due to study limitations.
Based on stroke recovery and dementia studies. CAVIN trial (n=469) showed significant cognitive improvements. Meta-analysis found modest effect size (0.439 SMD). Limited data in healthy populations. Most evidence from clinical populations with cerebrovascular issues.
AI-estimated from published studies. Interpret as directional guidance.
Vinpocetine has a higher evidence score (5.5/10 vs 4/10) and wins in 2 of 3 categories.
For sharpen focus, Noopept has a higher relevance score (75 vs 70).
No known interactions between Noopept and Vinpocetine have been documented in our database. However, always consult a healthcare provider before combining supplements.